127 related articles for article (PubMed ID: 8184599)
1. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
[TBL] [Abstract][Full Text] [Related]
2. Development and small-scale production of a severely heated factor VIII concentrate.
Knevelman A; de Wit HJ; Potstra P; vd Does JA
Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
[TBL] [Abstract][Full Text] [Related]
3. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
4. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
Roberts PL; Hart H
Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
[TBL] [Abstract][Full Text] [Related]
6. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
7. The influence of pH on heat denaturation of anti-haemophilic cryoprecipitate.
Skjønsberg OH; Gravem K; Kierulf P; Vaeret A; Godal HC
Thromb Res; 1987 Jul; 47(2):183-90. PubMed ID: 3116715
[TBL] [Abstract][Full Text] [Related]
8. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy.
Savage M; Torres J; Franks L; Masecar B; Hotta J
Biologicals; 1998 Jun; 26(2):119-24. PubMed ID: 9811517
[TBL] [Abstract][Full Text] [Related]
9. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
[TBL] [Abstract][Full Text] [Related]
10. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
Branović K; Gebauer B; Trescec A; Benko B
Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
[TBL] [Abstract][Full Text] [Related]
11. Severe heat treatment of freeze-dried coagulation factor concentrates: is hotter necessarily better?
Roberts PL
Vox Sang; 1995; 68(1):61-2. PubMed ID: 7725674
[No Abstract] [Full Text] [Related]
12. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
[TBL] [Abstract][Full Text] [Related]
13. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
[No Abstract] [Full Text] [Related]
14. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
[TBL] [Abstract][Full Text] [Related]
15. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
[TBL] [Abstract][Full Text] [Related]
16. von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity).
Oates A; Polmear E; Herrington R; Farrugia A; Sykes S; Raines G; Aumann H; Street A
Thromb Res; 1992 Feb; 65(3):389-99. PubMed ID: 1631803
[TBL] [Abstract][Full Text] [Related]
17. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
[TBL] [Abstract][Full Text] [Related]
18. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
19. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
[TBL] [Abstract][Full Text] [Related]
20. Severe heat treatment of freeze-dried coagulation factor concentrate: is hotter necessarily better?
Rubinstein DB
Vox Sang; 1995; 69(3):263-4. PubMed ID: 8578745
[No Abstract] [Full Text] [Related]
[Next] [New Search]